NEC to Use AI for Drug Development
Tokyo, May 27 (Jiji Press)--Japan's NEC Corp. <6701> said Monday it will start drug development using its artificial intelligence technology.
Cutting-edge AI technology will be used to analyze gene information for immune therapy, which utilizes the patient's own immune system to fight cancer and other diseases.
For starters, the electronics maker will work with French biotechnology company Transgene SA to start joint clinical trials for cancer immunotherapy in the United States and elsewhere by year-end.
A therapy method using so-called individual neoantigen vaccines will be examined in the trials.
NEC's AI will analyze the gene information of patients with recurrent cancer and identify abnormal gene information peculiar to cancer cells.
[Copyright The Jiji Press, Ltd.]